Prognostic Significance of Specific Anti-WT1 IgG Antibody Level in Plasma in Patients with Ovarian Carcinoma

Overview

Journal Cancer Med

Specialty Oncology

Date 2014 Apr 10

PMID 24715586

Citations 7

Authors

Charlotta Andersson

Yusuke Oji

Nina Ohlson

Sihan Wang

Xingru Li

Ulrika Ottander

Eva Lundin

Haruo Sugiyama

Aihong Li

Affiliations

Soon will be listed here.

Abstract

Ovarian carcinoma (OC) has a poor prognosis and lack early effective screening markers. Wilm's tumor gene 1 (WT1) is overexpressed in OCs. Therefore, it is of great interest to investigate whether WT1-specific antibody (Ab) measurements in plasma can serve as a biomarker of anti-OC response, and is of importance in relation to patient prognosis. Peripheral blood samples were obtained from a total of 103 women with ovarian tumors with median being 1 day (range 0-48 days) before operation. WT1 IgG Ab levels were evaluated using enzyme-linked immunosorbent assay (ELISA). Immunohistochemical analysis of WT1 protein expression was performed on OC tissue samples. We found that low-WT1 Ab level in plasma was related to improved survival in patients diagnosed at stages III-IV and grade 3 carcinomas. Positive WT1 protein staining on OC tissue samples had a negative impact on survival in the entire cohort, both overall survival (OS) (P = 0.046) and progression-free survival (PFS) (P = 0.006), but not in the serous OC subtype. Combining WT1 IgG Ab levels and WT1 staining, patients with high-WT1 IgG Ab levels in plasma and positive WT1 protein staining in cancer tissues had shorter survival, with a significant association in PFS (P = 0.016). These results indicated that WT1 Ab measurements in plasma and WT1 staining in tissue specimens could be useful as biomarkers for patient outcome in the high-risk subtypes of OCs for postoperative individualized therapy.

Citing Articles

WT1: The Hinge Between Anemia Correction and Cancer Development in Chronic Kidney Disease.

Lee W, Chiu C, Chu T, Chien Y Front Cell Dev Biol. 2022; 10:876723.

PMID: 35465313 PMC: 9019781. DOI: 10.3389/fcell.2022.876723.

Research Progress on the Mechanism Between Polycystic Ovary Syndrome and Abnormal Endometrium.

Xue Z, Li J, Feng J, Han H, Zhao J, Zhang J Front Physiol. 2022; 12:788772.

PMID: 34975540 PMC: 8718643. DOI: 10.3389/fphys.2021.788772.

Ca as a therapeutic target in cancer.

Gross S, Mallu P, Joshi H, Schultz B, Go C, Soboloff J Adv Cancer Res. 2020; 148:233-317.

PMID: 32723565 PMC: 7412871. DOI: 10.1016/bs.acr.2020.05.003.

EGR-mediated control of STIM expression and function.

Go C, Gross S, Hooper R, Soboloff J Cell Calcium. 2018; 77:58-67.

PMID: 30553973 PMC: 6467086. DOI: 10.1016/j.ceca.2018.12.003.

Wilms' tumor 1 (WT1) as a prognosis factor in gynecological cancers: A meta-analysis.

Lu J, Gu Y, Li Q, Zhong H, Wang X, Zheng Z Medicine (Baltimore). 2018; 97(28):e11485.

PMID: 29995811 PMC: 6076078. DOI: 10.1097/MD.0000000000011485.

References

Keilholz U, Letsch A, Busse A, Asemissen A, Bauer S, Blau I . A clinical and immunologic phase 2 trial of Wilms tumor gene product 1 (WT1) peptide vaccination in patients with AML and MDS. Blood. 2009; 113(26):6541-8. DOI: 10.1182/blood-2009-02-202598. View

Waldstrom M, Grove A . Immunohistochemical expression of wilms tumor gene protein in different histologic subtypes of ovarian carcinomas. Arch Pathol Lab Med. 2005; 129(1):85-8. DOI: 10.5858/2005-129-85-IEOWTG. View

Elisseeva O, Oka Y, Tsuboi A, Ogata K, Wu F, Kim E . Humoral immune responses against Wilms tumor gene WT1 product in patients with hematopoietic malignancies. Blood. 2002; 99(9):3272-9. DOI: 10.1182/blood.v99.9.3272. View

Wu F, Oka Y, Tsuboi A, Elisseeva O, Ogata K, Nakajima H . Th1-biased humoral immune responses against Wilms tumor gene WT1 product in the patients with hematopoietic malignancies. Leukemia. 2004; 19(2):268-74. DOI: 10.1038/sj.leu.2403539. View

Soslow R . Histologic subtypes of ovarian carcinoma: an overview. Int J Gynecol Pathol. 2008; 27(2):161-74. DOI: 10.1097/PGP.0b013e31815ea812. View

Das P, Bast Jr R . Early detection of ovarian cancer. Biomark Med. 2010; 2(3):291-303. PMC: 2930760. DOI: 10.2217/17520363.2.3.291. View

Loeb D, Evron E, Patel C, Sharma P, Niranjan B, Buluwela L . Wilms' tumor suppressor gene (WT1) is expressed in primary breast tumors despite tumor-specific promoter methylation. Cancer Res. 2001; 61(3):921-5. View

Klint A, Engholm G, Storm H, Tryggvadottir L, Gislum M, Hakulinen T . Trends in survival of patients diagnosed with cancer of the digestive organs in the Nordic countries 1964-2003 followed up to the end of 2006. Acta Oncol. 2010; 49(5):578-607. DOI: 10.3109/02841861003739330. View

Inoue K, Ogawa H, Sonoda Y, Kimura T, SAKABE H, Oka Y . Aberrant overexpression of the Wilms tumor gene (WT1) in human leukemia. Blood. 1997; 89(4):1405-12. View

10.

Schwartz D, Kardia S, Shedden K, Kuick R, Michailidis G, Taylor J . Gene expression in ovarian cancer reflects both morphology and biological behavior, distinguishing clear cell from other poor-prognosis ovarian carcinomas. Cancer Res. 2002; 62(16):4722-9. View

11.

Silberstein G, Van Horn K, Strickland P, Roberts Jr C, DANIEL C . Altered expression of the WT1 wilms tumor suppressor gene in human breast cancer. Proc Natl Acad Sci U S A. 1997; 94(15):8132-7. PMC: 21569. DOI: 10.1073/pnas.94.15.8132. View

12.

Svedberg H, Richter J, Gullberg U . Forced expression of the Wilms tumor 1 (WT1) gene inhibits proliferation of human hematopoietic CD34(+) progenitor cells. Leukemia. 2001; 15(12):1914-22. DOI: 10.1038/sj.leu.2402303. View

13.

Vermeij R, de Bock G, Leffers N, ten Hoor K, Schulze U, Hollema H . Tumor-infiltrating cytotoxic T lymphocytes as independent prognostic factor in epithelial ovarian cancer with wilms tumor protein 1 overexpression. J Immunother. 2011; 34(6):516-23. DOI: 10.1097/CJI.0b013e31821e012f. View

14.

Cathro H, Stoler M . The utility of calretinin, inhibin, and WT1 immunohistochemical staining in the differential diagnosis of ovarian tumors. Hum Pathol. 2005; 36(2):195-201. DOI: 10.1016/j.humpath.2004.11.011. View

15.

Gaiger A, Reese V, Disis M, Cheever M . Immunity to WT1 in the animal model and in patients with acute myeloid leukemia. Blood. 2000; 96(4):1480-9. View

16.

Gao L, Bellantuono I, Elsasser A, Marley S, Gordon M, Goldman J . Selective elimination of leukemic CD34(+) progenitor cells by cytotoxic T lymphocytes specific for WT1. Blood. 2000; 95(7):2198-203. View

17.

Oji Y, Kitamura Y, Kamino E, Kitano A, Sawabata N, Inoue M . WT1 IgG antibody for early detection of nonsmall cell lung cancer and as its prognostic factor. Int J Cancer. 2009; 125(2):381-7. DOI: 10.1002/ijc.24367. View

18.

Shimizu M, Toki T, Takagi Y, Konishi I, Fujii S . Immunohistochemical detection of the Wilms' tumor gene (WT1) in epithelial ovarian tumors. Int J Gynecol Pathol. 2000; 19(2):158-63. DOI: 10.1097/00004347-200004000-00010. View

19.

Nakatsuka S, Oji Y, Horiuchi T, Kanda T, Kitagawa M, Takeuchi T . Immunohistochemical detection of WT1 protein in a variety of cancer cells. Mod Pathol. 2006; 19(6):804-14. DOI: 10.1038/modpathol.3800588. View

20.

du Bois A, Luck H, Meier W, Adams H, Mobus V, Costa S . A randomized clinical trial of cisplatin/paclitaxel versus carboplatin/paclitaxel as first-line treatment of ovarian cancer. J Natl Cancer Inst. 2003; 95(17):1320-9. DOI: 10.1093/jnci/djg036. View